A

Acrivon Therapeutics
D

ACRV

5.56000
USD
-0.30
(-5.12%)
مغلق
حجم التداول
96
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
173,117,806
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأخبار
المقالات

العنوان: Acrivon Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.